|
|
Post by sayhey24 on Jun 14, 2023 6:20:00 GMT -5
Aged - I have to keep trying. Maybe it could be like cigarettes every time you feel hungry you take a puff - HA!
Peter said "the pulsatile administration of MKC253 achieved with our proprietary Technosphere delivery technology appears to avoid the dose-limiting vomiting characteristically associated with GLP-1 and replaces a physiological response lost in patients with diabetes that cannot be replicated by other forms of GLP-1"
Why was it pulsatile? Why does this make it different? I am trying to get to the bottom of what he was thinking so I will keep trying. Albert's $90B and Ozempic's 2.5m scripts are stuck in my head.
If you have better papers on glp-1s please post so I can pass some time during MNKD's low key ADA2023 while I keep trying to get hold of the expert.
|
|
|
|
Post by prcgorman2 on Jun 14, 2023 6:28:30 GMT -5
It is an interesting topic. Take a puff everytime you feel hungry. That sounds bad, but the construction of the analog version might make that not bad if the puffs could be limited to a few times a day. Instead of reching for a bag of chips, reach for a dreamboat, and a glass of water.
Subcutaneous injection leaking into tissues for most of a week is really going to put a strain on the analog I would think as compared to instantaneous administration to the bloodstream like the body naturally does. I assume an analog would still be necessary but only for 1 to 3 hours because you also have to eat. The body still needs nutrition. But staving off the hunger for an hour or two might be all that’s needed. If the trade-off of a few puffs a day is lack of nausea, I don’t know, you might be on to something.
|
|
|
|
Post by sportsrancho on Jun 14, 2023 7:36:22 GMT -5
Pass the dreamboat!
|
|
|
|
Post by prcgorman2 on Jun 14, 2023 8:23:13 GMT -5
There's an inhalable analog for GLP-1 that's been around for over 100 years. They're called cigarettes. TS version would likely be better (but perhaps not more profitable).
|
|
|
|
Post by mayday on Jun 14, 2023 8:25:55 GMT -5
Don't bogart that Dreamboat my friend.... |
|
|
|
Post by prcgorman2 on Jun 14, 2023 8:30:21 GMT -5
sayhey24 - Think "1 to 2 hour TS GLP-1 analog". Don't need a week or a month. Just need dealing with the hunger craving which is not all day, but usually only 2 or 3 times a day.
|
|
|
|
Post by hellodolly on Jun 14, 2023 9:00:56 GMT -5
Don't bogart that Dreamboat my friend.... Bring a bag of munchies, too. |
|
|
|
Post by dh4mizzou on Jun 14, 2023 9:01:02 GMT -5
Am I being too naive in thinking that this would be a perfect scenario for V-Go? Feeling a hunger pang, push the button on the V-Go device to deliver the GLP-1.
|
|
|
|
Post by prcgorman2 on Jun 14, 2023 9:44:10 GMT -5
Am I being too naive in thinking that this would be a perfect scenario for V-Go? Feeling a hunger pang, push the button on the V-Go device to deliver the GLP-1. For those who would prefer needles over the dreamboat inhaler? (V-Go would be good for those with COPD...)
|
|
limo
Researcher
Posts: 82
|
Post by limo on Jun 15, 2023 0:55:50 GMT -5
David Kendall our ex cmo is currently working on a Glp1 and various other peptides for weight loss. Zealand pharma are presenting at the ADA. If TS glp1 could be a possibility, he would know and would pursue it.
|
|
|
|
Post by sayhey24 on Jun 26, 2023 9:13:16 GMT -5
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Jun 26, 2023 15:24:57 GMT -5
David Kendall our ex cmo is currently working on a Glp1 and various other peptides for weight loss. Zealand pharma are presenting at the ADA. If TS glp1 could be a possibility, he would know and would pursue it. Don't worry, limo, TS technology is protected by MNKD's patent. Besides, in his short time at MNKD, he couldn't have gathered anywhere near the knowledge necessary to pursue that with Zealand. |
|
|
|
Post by sayhey24 on Jun 27, 2023 6:20:44 GMT -5
David Kendall our ex cmo is currently working on a Glp1 and various other peptides for weight loss. Zealand pharma are presenting at the ADA. If TS glp1 could be a possibility, he would know and would pursue it. Do you have a link to what he presented at ADA? As we can see from Nova and Pfizer there are issues taking a pill. Maybe if he has a good glp1 candidate TS could be the solution. I am not sure he was aware of the work Peter did since Mike did not seem to know about it. |
|
limo
Researcher
Posts: 82
|
Post by limo on Jun 27, 2023 7:54:28 GMT -5
|
|
|
|
Post by Clement on Jun 27, 2023 8:36:15 GMT -5
"Treatment with survodutide did not show unexpected safety or tolerability issues. Serious adverse events were reported by 4.2% of participants on survodutide versus 6.5% of those on placebo.1 Treatment discontinuation due to adverse events occurred in 24.6% and 3.9% of participants, respectively, mainly due to gastrointestinal adverse events.1 Most treatment discontinuations due to adverse events occurred during the rapid dose-escalation phase and may potentially be mitigated with more gradual dose escalation.1 The adverse events reported were similar to those expected with the GLP1-R agonist class of drugs.1" The word "unexpected" in the first sentence is amusing. |
|
